Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Long-Term Investments (2018 - 2025)

Historic Long-Term Investments for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $237760.0.

  • BioNexus Gene Lab's Long-Term Investments fell 8807.73% to $237760.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $237760.0, marking a year-over-year decrease of 8807.73%. This contributed to the annual value of $1.3 million for FY2024, which is 2557.11% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Long-Term Investments stood at $237760.0, which was down 8807.73% from $1.2 million recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Long-Term Investments high stood at $2.0 million for Q3 2024, and its period low was $237760.0 during Q3 2025.
  • Moreover, its 5-year median value for Long-Term Investments was $1.2 million (2022), whereas its average is $1.1 million.
  • In the last 5 years, BioNexus Gene Lab's Long-Term Investments soared by 3557989.36% in 2021 and then plummeted by 8807.73% in 2025.
  • BioNexus Gene Lab's Long-Term Investments (Quarter) stood at $749027.0 in 2021, then skyrocketed by 53.65% to $1.2 million in 2022, then soared by 47.7% to $1.7 million in 2023, then fell by 25.57% to $1.3 million in 2024, then crashed by 81.21% to $237760.0 in 2025.
  • Its Long-Term Investments stands at $237760.0 for Q3 2025, versus $1.2 million for Q2 2025 and $1.3 million for Q4 2024.